Literature DB >> 17884829

Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study.

Matthew E Falagas1, Petros I Rafailidis, Diamantis Kofteridis, Simona Virtzili, Fotini C Chelvatzoglou, Vassiliki Papaioannou, Sofia Maraki, George Samonis, Argyris Michalopoulos.   

Abstract

BACKGROUND: Carbapenems are frequently used to treat infections due to extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Thus, the emergence of infections due to carbapenem-resistant K. pneumoniae (CRKp) is a major public health concern.
OBJECTIVES: To identify risk factors associated with the development of CRKp infections.
METHODS: We conducted a matched case-control study in two hospitals (Henry Dunant Hospital, Athens, Greece and University Hospital of Heraklion, Crete, Greece). The controls were selected among patients with carbapenem-susceptible K. pneumoniae (CSKp) and were matched with CRKp cases for site of infection.
RESULTS: One hundred and six patients were included in our study (53 cases and 53 controls). Mortality was 30.1% and 33.9% for patients with CRKp and CSKp infections, respectively (P = 0.83). Bivariable analysis showed that exposure to anti-pseudomonas penicillins (P = 0.004), carbapenems (P = 0.01), quinolones (P < 0.001) and glycopeptides (P < 0.001), as well as admission to the intensive care unit (P = 0.002), tracheostomy (P = 0.02), chronic obstructive pulmonary disease (P = 0.04), surgery with use of foreign body (P = 0.04) and mechanical ventilation (P = 0.02) were associated with CRKp infection. The multivariable analysis showed that exposure to fluoroquinolones [odds ratio (OR) 4.54, 95% confidence intervals (CIs) 1.78-11.54, P = 0.001] and exposure to antipseudomonal penicillins (OR 2.57, 95% CI 1.00-6.71, P = 0.04) were independent risk factors for CRKp infections.
CONCLUSIONS: Our data suggest that prior exposure to fluoroquinolones and antipseudomonal penicillins are independent risk factors for the development of CRKp infections.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17884829     DOI: 10.1093/jac/dkm356

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  71 in total

1.  First outbreak of KPC-3-producing Klebsiella pneumoniae (ST258) clinical isolates in a Mexican Medical Center.

Authors:  Patricia Rodríguez-Zulueta; Jesús Silva-Sánchez; Humberto Barrios; Javier Reyes-Mar; Francisco Vélez-Pérez; Sara Arroyo-Escalante; Luis Ochoa-Carrera; Gabriela Delgado-Sapien; María Del Rosario Morales-Espinoza; Elsa Tamayo-Legorreta; Rigoberto Hernández-Castro; Ulises Garza-Ramos
Journal:  Antimicrob Agents Chemother       Date:  2013-06-03       Impact factor: 5.191

2.  Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Authors:  Michael J Satlin; Santosh Vardhana; Rosemary Soave; Tsiporah B Shore; Tomer M Mark; Samantha E Jacobs; Thomas J Walsh; Usama Gergis
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-03       Impact factor: 5.742

3.  Co-colonization by multidrug-resistant bacteria in two Greek intensive care units.

Authors:  M Papadimitriou-Olivgeris; I Spiliopoulou; M Christofidou; D Logothetis; P Manolopoulou; V Dodou; F Fligou; M Marangos; E D Anastassiou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-07-15       Impact factor: 3.267

4.  Evaluating antibiotic stewardship programs in patients with bacteremia using administrative data: a cohort study.

Authors:  J Boel; M Søgaard; V Andreasen; J O Jarløv; M Arpi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-17       Impact factor: 3.267

5.  Reducing carbapenem prescribing in high-use settings: it is possible, and it is good to talk.

Authors:  Nicola Jane Fawcett
Journal:  Intern Emerg Med       Date:  2018-10-06       Impact factor: 3.397

Review 6.  Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance.

Authors:  Vered Schechner; Elizabeth Temkin; Stephan Harbarth; Yehuda Carmeli; Mitchell J Schwaber
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

Review 7.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

8.  A model for predicting nosocomial carbapenem-resistant Klebsiella pneumoniae infection.

Authors:  Duo Yang; Zeqiang Xie; Xuli Xin; Wenying Xue; Man Zhang
Journal:  Biomed Rep       Date:  2016-09-07

9.  Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case-control study.

Authors:  G B Orsi; A Bencardino; A Vena; A Carattoli; C Venditti; M Falcone; A Giordano; M Venditti
Journal:  Infection       Date:  2012-10-16       Impact factor: 3.553

10.  Detection of plasmid-mediated KPC-producing Klebsiella pneumoniae in Ottawa, Canada: evidence of intrahospital transmission.

Authors:  David Goldfarb; Sarah-Beth Harvey; Kelsi Jessamine; Peter Jessamine; Baldwin Toye; Marc Desjardins
Journal:  J Clin Microbiol       Date:  2009-04-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.